AbbVie에 대한 매도 수량은 투자자에게 AbbVie의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

AbbVie (NYSE:ABBV) 주식, 공매도 수량 보고

AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Equities

News

Previews

Tech

Trading Ideas

ABBV

AGYS

ASML

BJRI

CHKP

CHTR

CMCSA

DECK

GATX

GOOG

GOOGL

JNPR

NFLX

NXPI

ODFL

ORLY

SKYW

SPOT

TSLA

VRSN

S&amp;P 500 기업들 중 약 14%가 6월 분기 실적을 발표했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.

테슬라, 알파벳, GM 및 포드가 이번 주 실적 발표 주도하며 상승세 유지 위해 고군분투

Biotech

Large Cap

Sector ETFs

Health Care

Small Cap

Global

Exclusives

ETFs

ALNY

AMGN

HRTS

테마(Tema) ETFs의 설립자이자 CEO인 마우리츠 팟(Maurits Pot)은 비만 치료를 위한 GLP-1 약물 시장은 1조 달러 이상으로 급등할 것으로 예상된다고 벤징가(Benzinga)와의 독점 인터뷰에서 그의 낙관적인 예측을 공유했다. 

단독: GLP-1 체중 감량 약물은 수조 달러 규모의 시장 가능성, 테마 ETFs CEO의 전망

AbbVie Inc

ABBVIE ORD

Guidance

Abbvie SAys Q3 2024 Adj Diluted EPS Guidance Range, Including Impact Of Q3 Acquired IPR&D And Milestones Expense Is $2.88-$2.92

General

AbbVie Reported GAAP & Adjusted Non-GAAP Earnings For Q3 Expected To Include Acquired IPR&D & Milestones Expense Of $82M On Pre-Tax Basis; FY Adj EPS Guidance Range, Including Impact Of Q3 2024 Acquired IPR&D And Milestones Expense, Is $10.67-$10.87; IPR&D & Milestones Expense Representing Unfavorable Impact Of $0.04 To Both GAAP Diluted Eps & Adj Non-GAAP Diluted EPS For Q3

Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Humira, one of the world&#8217;s most expensive and widely used drugs.
Humira, approved by the FDA in 2002, has long dominated the market, treating conditions like arthritis and Crohn&#8217;s disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39228916/abbvies-arthritis-drug-humira-retains-market-dominance-despite-biosimilar-competition-challenges-" rel="noreferrer noopener">AbbVie&#8217;s Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability</a>.
However, it has faced criticism for its high pricing and extended market exclusivity, which ended in January 2023.
Blue Shield, which processes around 40,000 Humira prescriptions annually, spends more on the drug than any other medication for its members, making this price-cutting move both timely and essential for addressing the rising cost of healthcare.
The nonprofit health plan <a target="_blank" href="https://news.blueshieldca.com/2024/10/01/blue-shield-of-california-slashes-cost-of-worlds-best-selling-drug" rel="noreferrer noopener">announced</a> that it would purchase Fresenius Kabi&#8217;s FDA-approved biosimilar adalimumab-aacf at a net price of $525 per monthly dose, a significant reduction from Humira&#8217;s market-reported price of $2,100.
The deal, facilitated by Evio Pharmacy Solutions, aims to eliminate excessive markups typically imposed by pharmacy benefit managers (PBMs) in the current drug supply chain.
The new pricing model is part of Blue Shield&#8217;s Pharmacy Care Reimagined initiative, which rethinks traditional PBM structures to ensure more transparent and affordable pricing.
The aligned incentives and simplified supply chain have enabled Blue Shield to provide Fresenius Kabi&#8217;s biosimilar to its members. Starting in January 2025, most commercial members are expected to pay $0 out of pocket.
This move sets a critical precedent as the pharmaceutical industry approaches a &#8220;biosimilar cliff,&#8221; with more low-cost alternatives entering the market.
Last month, UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) said it would remove Humira from some of its preferred reimbursement lists starting January 1, 2025. The company will recommend lower-cost <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40820758/unitedhealth-follows-competitors-replaces-humira-with-lower-cost-biosimilars" rel="noreferrer noopener">biosimilar versions instead</a>.
Price Action: ABBV stock is down 0.45% at $195.93 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41169322/amazons-profitable-essential-merchandise-efficiency-gains-set-to-drive-growth-analyst" target="_blank" rel="noreferrer noopener">Amazon&#8217;s Profitable Essential Merchandise, Efficiency Gains Set To Drive Growth: Analyst</a></li>
</ul>
Photo via Wikimedia Commons

Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal

In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and its primary competitors in the Biotechnology industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>AbbVie Background</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie Inc</td>
<td>65.83</td>
<td>51.29</td>
<td>6.34</td>
<td>18.4%</td>
<td>$5.0</td>
<td>$10.26</td>
<td>4.31%</td>
</tr>
<tr>
<td>Amgen Inc</td>
<td>55.13</td>
<td>29</td>
<td>5.58</td>
<td>13.63%</td>
<td>$3.0</td>
<td>$5.15</td>
<td>20.07%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc</td>
<td>27.54</td>
<td>4.07</td>
<td>8.82</td>
<td>5.19%</td>
<td>$1.76</td>
<td>$3.07</td>
<td>12.32%</td>
</tr>
<tr>
<td>Gilead Sciences Inc</td>
<td>103.33</td>
<td>5.77</td>
<td>3.81</td>
<td>9.01%</td>
<td>$2.98</td>
<td>$5.41</td>
<td>5.36%</td>
</tr>
<tr>
<td>Biogen Inc</td>
<td>23.80</td>
<td>1.73</td>
<td>2.85</td>
<td>3.75%</td>
<td>$0.92</td>
<td>$1.92</td>
<td>0.36%</td>
</tr>
<tr>
<td>United Therapeutics Corp</td>
<td>16.20</td>
<td>2.75</td>
<td>6.63</td>
<td>5.04%</td>
<td>$0.39</td>
<td>$0.64</td>
<td>19.85%</td>
</tr>
<tr>
<td>Genmab AS</td>
<td>18.72</td>
<td>3.24</td>
<td>5.45</td>
<td>4.44%</td>
<td>$2.15</td>
<td>$5.21</td>
<td>29.58%</td>
</tr>
<tr>
<td>Biomarin Pharmaceutical Inc</td>
<td>52.77</td>
<td>2.51</td>
<td>5.23</td>
<td>2.07%</td>
<td>$0.16</td>
<td>$0.58</td>
<td>19.61%</td>
</tr>
<tr>
<td>Incyte Corp</td>
<td>164.95</td>
<td>4.35</td>
<td>3.92</td>
<td>-10.6%</td>
<td>$-0.37</td>
<td>$0.97</td>
<td>9.34%</td>
</tr>
<tr>
<td>Sarepta Therapeutics Inc</td>
<td>163.36</td>
<td>10.85</td>
<td>7.96</td>
<td>0.63%</td>
<td>$0.03</td>
<td>$0.32</td>
<td>38.93%</td>
</tr>
<tr>
<td>Neurocrine Biosciences Inc</td>
<td>34.32</td>
<td>4.59</td>
<td>5.52</td>
<td>2.66%</td>
<td>$0.16</td>
<td>$0.58</td>
<td>30.37%</td>
</tr>
<tr>
<td>Roivant Sciences Ltd</td>
<td>1.97</td>
<td>1.53</td>
<td>59.62</td>
<td>1.67%</td>
<td>$0.09</td>
<td>$0.05</td>
<td>154.96%</td>
</tr>
<tr>
<td>Exelixis Inc</td>
<td>22.84</td>
<td>3.57</td>
<td>4.05</td>
<td>10.65%</td>
<td>$0.28</td>
<td>$0.62</td>
<td>35.61%</td>
</tr>
<tr>
<td>Average</td>
<td>57.08</td>
<td>6.16</td>
<td>9.95</td>
<td>4.01%</td>
<td>$0.96</td>
<td>$2.04</td>
<td>31.36%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>After examining AbbVie, the following trends can be inferred: 
<ul>
<li>
Notably, the current Price to Earnings ratio for this stock, 65.83, is 1.15x above the industry norm, reflecting a higher valuation relative to the industry.
</li>
<li>
It could be trading at a premium in relation to its book value, as indicated by its Price to Book ratio of 51.29 which exceeds the industry average by 8.33x.
</li>
<li>
With a relatively low Price to Sales ratio of 6.34, which is 0.64x the industry average, the stock might be considered undervalued based on sales performance.
</li>
<li>
The Return on Equity (ROE) of 18.4% is 14.39% above the industry average, highlighting efficient use of equity to generate profits.
</li>
<li>
With higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $5.0 Billion, which is 5.21x above the industry average, the company demonstrates stronger profitability and robust cash flow generation.
</li>
<li>
With higher gross profit of $10.26 Billion, which indicates 5.03x above the industry average, the company demonstrates stronger profitability and higher earnings from its core operations.
</li>
<li>
The company's revenue growth of 4.31% is significantly below the industry average of 31.36%. This suggests a potential struggle in generating increased sales volume.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727967651_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio indicates the proportion of debt and equity used by a company to finance its assets and operations.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In terms of the Debt-to-Equity ratio, AbbVie can be assessed by comparing it to its top 4 peers, resulting in the following observations:
<ul>
<li>
In terms of the debt-to-equity ratio, AbbVie is positioned in the middle among its top 4 peers.
</li>
<li>
This suggests a relatively balanced financial structure, where the company maintains a moderate level of debt while also utilizing equity financing with a debt-to-equity ratio of 10.42.
</li>
</ul>
<h3>Key Takeaways</h3>
For AbbVie in the Biotechnology industry, the PE, PB, and PS ratios indicate high valuation compared to peers, suggesting potential overvaluation. Conversely, the high ROE, EBITDA, and gross profit ratios reflect strong profitability and operational efficiency relative to industry competitors. The low revenue growth rate may pose a challenge for AbbVie in maintaining its high valuation multiples.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Markets

Comparing AbbVie With Industry Competitors In Biotechnology Industry

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) revealed 15 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 46% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $149,555, and 12 were calls, valued at $621,086.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $135.0 to $200.0 for AbbVie during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for AbbVie's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale activity within a strike price range from $135.0 to $200.0 in the last 30 days. 
<h3>AbbVie Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727966166_0_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.5</td>
<td>$8.3</td>
<td>$8.5</td>
<td>$200.00</td>
<td>$101.1K</td>
<td>7.4K</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$63.9</td>
<td>$61.25</td>
<td>$63.89</td>
<td>$135.00</td>
<td>$95.8K</td>
<td>196</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$32.95</td>
<td>$32.35</td>
<td>$32.9</td>
<td>$170.00</td>
<td>$78.9K</td>
<td>326</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$9.85</td>
<td>$9.65</td>
<td>$9.85</td>
<td>$195.00</td>
<td>$63.0K</td>
<td>1.1K</td>
<td style="text-align: right;">137</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$56.1</td>
<td>$55.2</td>
<td>$56.1</td>
<td>$150.00</td>
<td>$61.7K</td>
<td>34</td>
<td style="text-align: right;">7</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
After a thorough review of the options trading surrounding AbbVie, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is AbbVie Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,038,234, the ABBV's price is down by -0.42%, now at $196.0. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 27 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Behind the Scenes of AbbVie's Latest Options Trends

On Wednesday, the U.S. Department of Health and Human Services (HHS), working via the Centers for Medicare &amp; Medicaid Services (CMS), released final guidance for the second cycle of the <a href="https://www.benzinga.com/general/health-care">Medicare Drug Price Negotiation Program</a>.
This initiative <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-releases-final-guidance-second-cycle-historic-medicare-drug-price-negotiation-program" rel="noreferrer noopener">aims</a> to provide lower drug prices starting in 2026 and 2027.
It also ensures that people with Medicare can access these negotiated prices, expanding on the groundwork laid in the first cycle of negotiations.
The first round of negotiations focused on 10 specific drugs. Medicare recipients should save approximately $1.5 billion in out-of-pocket costs when the new prices take effect in 2026.
By February 2025, CMS will select up to 15 additional drugs for the second round of negotiations. The selected drugs will undergo negotiations in 2025, with new prices becoming effective in 2027.
They include: 
<ul>
<li>Novo Nordisk&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) diabetes drug, <a href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets">Ozempic,</a></li>
<li>Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) cancer drugs Ibrance and Xtandi</li>
<li>GSK Plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) asthma treatment Trelegy Ellipta</li>
<li>Teva Pharmaceutical Industries Ltd.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) Huntington&#8217;s disease drug Austedo, and</li>
<li>Abbvie Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) irritable bowel syndrome treatment Linzess.</li>
</ul>
CMS plans to improve patient-focused engagement during the second cycle of negotiations. It will also organize roundtable events and town hall meetings in 2025.
As Medicare Open Enrollment approaches on Oct. 15, beneficiaries can expect more cost-saving measures in the coming years. That includes a $2,000 annual cap on out-of-pocket drug costs starting in January 2025.
These changes build on other provisions of the Inflation Reduction Act, which was signed by President Joe Biden on Aug. 16, 2022. The legislation included a $35 monthly cap on insulin and free recommended vaccines for adults covered under Medicare Part D.
Monday, the U.S. Department of Health and Human Services (HHS) announced that Medicare enrollees will benefit from reduced prices on 54 drugs through Medicare Part B, effective from Oct. 1, 2024, to Dec. 31, 2024. Some Medicare beneficiaries could see daily savings ranging from $1 to as much as $3,854 on drugs included <a href="https://www.benzinga.com/general/biotech/24/10/41127143/us-hhs-reveal-cost-savings-for-54-prescription-drugs-including-novartis-cancer-drug-ozempic-could" target="_blank" rel="noreferrer noopener">in the rebate program</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41162084/amazon-prime-video-ramps-up-ads-taking-on-netflix-and-disney-in-streaming-battle" target="_blank" rel="noreferrer noopener">Amazon Prime Video Ramps Up Ads, Taking on Netflix and Disney+ in Streaming Battle</a>.</li>
</ul>
Image: Shutterstock

Government

TEVA

Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected

European Medicines Agency Says On September 25  European Commission Withdrew Marketing Authorization For Exviera In EU; Withdrawal Of Marketing Authorisation For Exviera Was At Request Of Marketing Authorisation Holder, AbbVie Deutschland GmbH & Co. KG; AbbVie Deutschland GmbH & Co. KG, Notified Commission Of Decision To Discontinue Marketing Of Exviera For Commercial Reasons

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/09/27/final-trades-meta-accenture-abbvie-and-disney.html">Halftime Report Final Trades</a>,&#8221; Kevin Simpson of Capital Wealth Planning said Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is <a href="https://www.benzinga.com/quote/META/analyst-ratings">hitting on all cylinders</a>.
On Sept. 26, Rosenblatt analyst Barton Crockett maintained Meta Platforms with a Buy and raised the price target from $643 to $811.
Brenda Vingiello of Sand Hill Global Advisors named Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) as her final trade.
On Sept. 26, Accenture reported fourth-quarter fiscal 2024 sales of $16.41 billion compared with the analyst consensus estimate of $16.39 billion, up 3% Y/Y in U.S. dollars and 5% in local currency. Revenues were above the midpoint of the company's guided range of $16.05 billion–$16.65 billion. The adjusted EPS of $2.79 topped the analyst consensus estimate of $2.77.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jason Snipe of Odyssey Capital Advisors said AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has a great pipeline.
On Sept. 26, AbbVie released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease.
Joseph M. Terranova of Virtus Investment Partners picked Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>), saying streaming profitability is going to be a lot higher than expected for the next year.
Walt Disney let go of at least 300 employees across multiple corporate departments. "We continually evaluate ways to invest in our businesses and more effectively manage our resources and costs to fuel the state-of-the-art creativity and innovation that consumers value and expect from Disney," Variety cites a company representative. The layoffs affected human resources, legal, finance and other <a href="https://www.benzinga.com/news/24/09/41045649/disney-trims-workforce-by-300-targets-corporate-departments-for-cost-management">departments in the U.S</a>.
Price Action:
<ul>
<li>Meta shares fell 0.1% to close at $567.36 during Friday's session.</li>
<li>Accenture shares fell 1.7% to settle at $349.70 on Friday.</li>
<li>AbbVie shares gained 1.5% to close at $194.79 during Friday's session.</li>
<li>Disney shares gained 0.9% to close at $96.01 on Friday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41075978/top-4-materials-stocks-that-may-implode-in-q3">Top 4 Materials Stocks That May Implode In Q3</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

Meta, Accenture, Disney And A Major Health Care Stock On CNBC's 'Final Trades'

AbbVie's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) short percent of float has fallen 8.18% since its last report. The company recently reported that it has 17.79 million shares sold short, which is 1.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AbbVie Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727469922_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AbbVie has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AbbVie's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AbbVie's peer group average for short interest as a percentage of float is 5.98%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(ABBV) - Analyzing AbbVie's Short Interest

On Thursday, the FDA approved&nbsp;Bristol Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">schizophrenia in adults</a>.
BMO Capital analyst notes that the FDA approval without a boxed warning is a significant positive for Bristol Myers shares.
The analyst notes that given that many prior antipsychotic medications received black box warnings due to increased mortality risks, particularly in elderly patients, Cobenfy&#8217;s absence of such a warning could significantly enhance its potential in treating Alzheimer&#8217;s related-psychosis, pending further clinical trials.
BMO projects peak sales of $2.4 billion for Cobenfy in schizophrenia and $3.9 billion in Alzheimer&#8217;s related-psychosis, raising the price target to $53 from $48, with a <a target="_blank" href="https://www.benzinga.com/quote/BMY/analyst-ratings" rel="noreferrer noopener">Market Perform rating</a>.
The analyst notes that Cobenfy will be priced at $1,850 for a 30-day supply or $22,500/year, representing a discount to previous expectations.
Truist Securities highlights that AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is also advancing emraclidine as a treatment for schizophrenia and Alzheimer&#8217;s disease-related psychosis.
According to Truist analysts, emraclidine differs from KarXT in its mechanism of action.
Despite emerging competition, Truist points out that KarXT holds a first-mover advantage and is ahead by at least two to three years.
Truist maintains the Buy rating and a price target of $62.
William Blair projects peak U.S. sales for Cobenfy to reach approximately $2 billion by 2030, driven solely by its use in treating schizophrenia.
However, if the drug is approved for additional indications, such as Alzheimer-related psychosis and adjunctive schizophrenia—both currently in Phase 3 trials—annual sales could rise to around $3 billion to $5 billion, pending positive results.
The analyst points out that although the label lacks a black box warning, it does include caution for urinary retention, elevated heart rate, reduced gastric motility, and angioedema.
Price Action: BMY stock is up 2.33% at $51.29&nbsp;at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41070911/fda-removes-clinical-hold-on-biomea-fusions-early-stage-trials-for-potential-diabetes-candidate" target="_blank" rel="noreferrer noopener">FDA Removes Clinical Hold On Biomea Fusion&#8217;s Early-Stage Trials For Potential Diabetes Candidate</a>.</li>
</ul>

Analyst Color

Price Target

Analyst Ratings

Movers

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential

- Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression.
- Biologics License Application (BLA) submission for accelerated approval is supported by data from the Phase 2 LUMINOSITY trial (M14-239). Review of the BLA will be conducted under FDA's Oncology Center of Excellence (OCE) Real-Time Oncology Review (RTOR) program.&nbsp;
- There are currently no approved anti-cancer therapies specifically for c-Met overexpressing NSCLC and if approved Teliso-V would be the first-in-class therapy for this patient population.&nbsp;
NORTH CHICAGO, Ill., Sept. 27, 2024 /PRNewswire/ --&nbsp;AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V) in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression.
Approximately 85% of lung cancers are classified as NSCLC1&nbsp;and despite advances in treatment, lung cancer remains the leading cause of cancer-related deaths throughout the world.2&nbsp;The c-Met protein is a receptor tyrosine kinase found to be overexpressed in approximately 25% of advanced EGFR wild type, nonsquamous NSCLC patients3&nbsp;and is associated with a poor prognosis.4,5,6 Teliso-V is being evaluated within this patient population who currently have very limited treatment options.&nbsp;

AbbVie Submits Biologics License Application To The FDA For Telisotuzumab Vedotin In Previously Treated Non-Small Cell Lung Cancer

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual return of 12.86%. Currently, AbbVie has a market capitalization of $338.87 billion. 
Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 10 years ago, it would be worth $3,322.37 today based on a price of $191.90 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727386222_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years

On Thursday, AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n41044273/abbvie-announces-positive-topline-results-from-phase-3-tempo-1-trial-evaluating-tavapadon-as-a-mon" rel="noreferrer noopener">early Parkinson&#8217;s disease</a>.
Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson&#8217;s disease. AbbVie added the drug candidate with its $8.7 billion&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36138732/abbvies-new-9b-neuroscience-space-deal-might-attract-ftc-scrutiny-analyst-signals" rel="noreferrer noopener">buyout of Cerevel Therapeutics</a>.
The TEMPO-1 trial evaluated the efficacy, safety and tolerability of two fixed doses (5 mg and 15 mg, once daily) of tavapadon as a monotherapy in adults with early Parkinson&#8217;s disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40820758/unitedhealth-follows-competitors-replaces-humira-with-lower-cost-biosimilars" rel="noreferrer noopener">UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars</a>.
The trial met its primary endpoint – patients treated with tavapadon in both dose groups experienced a statistically significant reduction (improvement) from baseline compared to placebo (placebo: +1.8; 5 mg: -9.7; 15 mg: -10.2 versus placebo) in the Movement Disorder Society &#8211; Unified Parkinson&#8217;s Disease Rating Scale (MDS-UPDRS) Parts II and III combined score at week 26.
MDS-UPDRS assesses motor and non-motor symptoms of Parkinson&#8217;s disease.
The TEMPO-1 trial also met the key secondary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor aspects of experiences of daily living (MDS-UPDRS Part II) in both tavapadon dose groups compared to placebo at week 26.
The safety profile observed in the TEMPO-1 trial was consistent with prior clinical trials. The majority of adverse events reported were mild to moderate in severity.
Full results from the TEMPO-1 study will be submitted for presentation at future medical meetings and used to support regulatory submissions of tavapadon as a treatment for Parkinson&#8217;s disease.
Topline results from TEMPO-2, the Phase 3 flexible-dose monotherapy trial for tavapadon, are expected by the end of 2024.
Price Action: ABBV stock is up 0.33% at $191.90 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41048142/visa-takes-on-financial-crime-acquires-ai-fraud-specialist-featurespace-strengthening-payment-se" target="_blank" rel="noreferrer noopener">Visa Takes On Financial Crime: Acquires AI Fraud Specialist Featurespace, Strengthening Payment Security</a>.</li>
</ul>
Photo via Shutterstock

AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease

AbbVie Announces Phase 3 TEMPO-1 Trial Results For Tavapadon As Monotherapy In Early Parkinson's Disease, Showing Significant Improvement In MDS-UPDRS Scores; Results From TEMPO-2 Flexible-Dose Trial Expected By Year-End 2024

AbbVie Announced Results From A New Post-Hoc Analysis From The Measure Up 1 And Measure Up 2 Phase 3 Studies Of Upadacitinib (15 mg Or 30 mg) In Patients With Moderate-to-severe Atopic Dermatitis

Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie.
Looking at options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) we detected 15 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $199,317 and 13, calls, for a total amount of $651,450.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $165.0 to $210.0 for AbbVie during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of AbbVie stands at 941.86, with a total volume reaching 2,530.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AbbVie, situated within the strike price corridor from $165.0 to $210.0, throughout the last 30 days.
<h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727202645_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$12.2</td>
<td>$12.0</td>
<td>$11.98</td>
<td>$195.00</td>
<td>$150.3K</td>
<td>559</td>
<td style="text-align: right;">291</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$9.2</td>
<td>$9.15</td>
<td>$9.18</td>
<td>$200.00</td>
<td>$108.8K</td>
<td>1.5K</td>
<td style="text-align: right;">237</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.73</td>
<td>$2.7</td>
<td>$2.73</td>
<td>$210.00</td>
<td>$96.7K</td>
<td>354</td>
<td style="text-align: right;">377</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$13.1</td>
<td>$12.95</td>
<td>$13.06</td>
<td>$185.00</td>
<td>$84.7K</td>
<td>3.1K</td>
<td style="text-align: right;">70</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$25.9</td>
<td>$25.5</td>
<td>$25.5</td>
<td>$170.00</td>
<td>$66.3K</td>
<td>550</td>
<td style="text-align: right;">36</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Where Is AbbVie Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,696,972, the price of ABBV is down by -0.11%, reaching $193.61.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 31 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

The experimental drug KarXT, developed by Karuna Therapeutics, is expected to receive FDA approval later this month (Sept. 26), marking a significant breakthrough in schizophrenia treatment.
If approved, KarXT would become the first novel schizophrenia drug in over 70 years, offering new hope for patients and medical professionals alike.
Schizophrenia, a mental disorder that affects approximately 3.8 million adults in the U.S., is often characterized by severe symptoms such as social isolation, memory issues and psychotic episodes.
Last year, Bristol-Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) acquired Karuna Therapeutics for $330 per share in cash for a total equity value of $14 billion, or $12.7 billion net of <a href="https://www.benzinga.com/markets/equities/23/12/36388646/bristol-myers-acquisition-of-karuna-therapeutics-paves-way-for-aggressive-global-marketing-of-ka" target="_blank" rel="noreferrer noopener">estimated cash acquired</a>. 
The Financial Times <a target="_blank" href="https://www.ft.com/content/427d37df-e2e9-4b67-87be-29f2a258de00" rel="noreferrer noopener">highlights</a> that existing treatments, mainly focused on blocking dopamine receptors, often come with serious side effects, including weight gain and involuntary movements.
Despite the enthusiasm surrounding KarXT, the complexity and financial constraints of the U.S. health care system could limit access to this new treatment.
High drug pricing could also hinder access; the Institute for Clinical and Economic Review has suggested KarXT be priced at up to $20,000 per year.
In August, AbbVie Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) completed the acquisition of Cerevel Therapeutics, another company focused on developing drugs for neurological disorders, for a total equity value of approximately $8.7 billion, or <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36138732/abbvies-new-9b-neuroscience-space-deal-might-attract-ftc-scrutiny-analyst-signals" rel="noreferrer noopener">$45 per share in cash</a>.
The challenges extend beyond the cost and availability of medications, the Financial Times report adds. Many individuals with mental health conditions, particularly schizophrenia, encounter law enforcement rather than health care professionals during crises.
While KarXT&#8217;s approval could represent a crucial step forward, many experts, including Michael Thompson, a criminal justice expert, say that more systemic changes are needed to ensure mental health care is accessible and effective, especially for vulnerable populations like the homeless, according to FT. 

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40963228/zevra-therapeutics-drug-becomes-first-fda-approved-treatment-for-ultra-rare-neurodegenerative-dis" target="_blank" rel="noreferrer noopener">Zevra Therapeutics&#8217; Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease</a></li>
</ul>
Photo via Pixabay.

Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years

Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) revealed 8 unusual trades.
Delving into the details, we found 37% of traders were bullish, while 12% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $325,314, and 4 were calls, valued at $527,350.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $165.0 to $195.0 for AbbVie during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AbbVie's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale trades within a strike price range from $165.0 to $195.0 in the last 30 days. 
<h3>AbbVie Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726859359_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$28.4</td>
<td>$27.15</td>
<td>$28.0</td>
<td>$165.00</td>
<td>$361.2K</td>
<td>1.4K</td>
<td>29</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.71</td>
<td>$180.00</td>
<td>$204.0K</td>
<td>8</td>
<td>553</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.1</td>
<td>$8.05</td>
<td>$8.1</td>
<td>$195.00</td>
<td>$101.2K</td>
<td>363</td>
<td>125</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$2.12</td>
<td>$1.83</td>
<td>$1.95</td>
<td>$195.00</td>
<td>$58.5K</td>
<td>3.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$18.25</td>
<td>$17.75</td>
<td>$17.98</td>
<td>$190.00</td>
<td>$35.9K</td>
<td>646</td>
<td>20</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Following our analysis of the options activities associated with AbbVie, we pivot to a closer look at the company's own performance.
<h3>Current Position of AbbVie</h3>
<ul>
<li>With a trading volume of 3,370,211, the price of ABBV is down by -0.39%, reaching $192.86.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 35 days from now.</li>
</ul>
<h3>Expert Opinions on AbbVie</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $209.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on AbbVie with a target price of $209. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Spotlight on AbbVie: Analyzing the Surge in Options Activity

In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) against its key competitors in the Biotechnology industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>AbbVie Background</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie Inc</td>
<td>64.53</td>
<td>50.28</td>
<td>6.22</td>
<td>18.4%</td>
<td>$5.0</td>
<td>$10.26</td>
<td>4.31%</td>
</tr>
<tr>
<td>Amgen Inc</td>
<td>57.40</td>
<td>30.19</td>
<td>5.81</td>
<td>13.63%</td>
<td>$3.0</td>
<td>$5.15</td>
<td>20.07%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc</td>
<td>30.15</td>
<td>4.45</td>
<td>9.66</td>
<td>5.19%</td>
<td>$1.76</td>
<td>$3.07</td>
<td>12.32%</td>
</tr>
<tr>
<td>Gilead Sciences Inc</td>
<td>102.32</td>
<td>5.71</td>
<td>3.78</td>
<td>9.01%</td>
<td>$2.98</td>
<td>$5.41</td>
<td>5.36%</td>
</tr>
<tr>
<td>Biogen Inc</td>
<td>24.92</td>
<td>1.81</td>
<td>2.98</td>
<td>3.75%</td>
<td>$0.92</td>
<td>$1.92</td>
<td>0.36%</td>
</tr>
<tr>
<td>Genmab AS</td>
<td>20.81</td>
<td>3.60</td>
<td>6.06</td>
<td>4.44%</td>
<td>$2.15</td>
<td>$5.21</td>
<td>29.58%</td>
</tr>
<tr>
<td>United Therapeutics Corp</td>
<td>15.74</td>
<td>2.68</td>
<td>6.44</td>
<td>5.04%</td>
<td>$0.39</td>
<td>$0.64</td>
<td>19.85%</td>
</tr>
<tr>
<td>Biomarin Pharmaceutical Inc</td>
<td>53.89</td>
<td>2.56</td>
<td>5.34</td>
<td>2.07%</td>
<td>$0.16</td>
<td>$0.58</td>
<td>19.61%</td>
</tr>
<tr>
<td>Incyte Corp</td>
<td>158.93</td>
<td>4.19</td>
<td>3.78</td>
<td>-10.6%</td>
<td>$-0.37</td>
<td>$0.97</td>
<td>9.34%</td>
</tr>
<tr>
<td>Neurocrine Biosciences Inc</td>
<td>36.10</td>
<td>4.82</td>
<td>5.81</td>
<td>2.66%</td>
<td>$0.16</td>
<td>$0.58</td>
<td>30.37%</td>
</tr>
<tr>
<td>Sarepta Therapeutics Inc</td>
<td>166.68</td>
<td>11.07</td>
<td>8.12</td>
<td>0.63%</td>
<td>$0.03</td>
<td>$0.32</td>
<td>38.93%</td>
</tr>
<tr>
<td>Roivant Sciences Ltd</td>
<td>2.09</td>
<td>1.63</td>
<td>63.42</td>
<td>1.67%</td>
<td>$0.09</td>
<td>$0.05</td>
<td>154.96%</td>
</tr>
<tr>
<td>Halozyme Therapeutics Inc</td>
<td>24.15</td>
<td>27.27</td>
<td>9.34</td>
<td>39.91%</td>
<td>$0.14</td>
<td>$0.19</td>
<td>4.67%</td>
</tr>
<tr>
<td>Average</td>
<td>57.77</td>
<td>8.33</td>
<td>10.88</td>
<td>6.45%</td>
<td>$0.95</td>
<td>$2.01</td>
<td>28.79%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Through a detailed examination of AbbVie, we can deduce the following trends: 
<ul>
<li>
The Price to Earnings ratio of 64.53 for this company is 1.12x above the industry average, indicating a premium valuation associated with the stock.
</li>
<li>
It could be trading at a premium in relation to its book value, as indicated by its Price to Book ratio of 50.28 which exceeds the industry average by 6.04x.
</li>
<li>
With a relatively low Price to Sales ratio of 6.22, which is 0.57x the industry average, the stock might be considered undervalued based on sales performance.
</li>
<li>
The company has a higher Return on Equity (ROE) of 18.4%, which is 11.95% above the industry average. This suggests efficient use of equity to generate profits and demonstrates profitability and growth potential.
</li>
<li>
The company exhibits higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $5.0 Billion, which is 5.26x above the industry average, implying stronger profitability and robust cash flow generation.
</li>
<li>
Compared to its industry, the company has higher gross profit of $10.26 Billion, which indicates 5.1x above the industry average, indicating stronger profitability and higher earnings from its core operations.
</li>
<li>
The company's revenue growth of 4.31% is significantly below the industry average of 28.79%. This suggests a potential struggle in generating increased sales volume.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726758052_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio helps evaluate the capital structure and financial leverage of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When assessing AbbVie against its top 4 peers using the Debt-to-Equity ratio, the following comparisons can be made:
<ul>
<li>
When evaluating the debt-to-equity ratio, AbbVie is in the middle position among its top 4 peers.
</li>
<li>
The company maintains a moderate level of debt relative to its equity with a debt-to-equity ratio of 10.42, suggesting a relatively balanced financial structure.
</li>
</ul>
<h3>Key Takeaways</h3>
For AbbVie, the PE, PB, and PS ratios are all high compared to its peers in the Biotechnology industry, indicating potentially overvalued stock. On the other hand, AbbVie's high ROE, EBITDA, and gross profit suggest strong profitability and operational efficiency relative to industry peers. However, the low revenue growth rate may raise concerns about the company's future performance compared to its competitors in the sector.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry

Ripple Therapeutics Announces Collaboration And Option-To-License Agreement With AbbVie To Develop Biodegradable Sustained Release Drug Delivery Implants For Glaucoma Management

AbbVie: $200 Peak (Rating Downgrade)

AbbVie: A Strong Investment Opportunity In Neurological And Oncology Breakthroughs

U.S. tweaks 2025 Medicare price negotiation process

AbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In Schizophrenia

The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst economic shifts, rising chronic illnesses, and strong growth projections in global revenues and biotechnology markets. Therefore, it could be wise to invest in pharma stocks such as AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Gilead Sciences (GILD), which could lead the next drug revolution. Read more... The pharmaceutical industry is driving the next drug revolution with AI and biotech innovations. Companies are using automation to streamline processes, boosting productivity and accuracy. Investors favor the sector for its steady profits, resilience during economic shifts, and sustained demand, driven by factors such as rising chronic illnesses.
Amid this favorable backdrop, investors could consider buying fundamentally strong pharmaceutical stocks: AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>), Bristol-Myers Squibb Company (<a href="https://stocknews.com/stock/BMY/">BMY</a>), and Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>).
In today's digital era, pharmaceutical firms are rapidly embracing AI to enhance biopharma manufacturing, drug development, and healthcare solutions. AI and machine learning are revolutionizing drug discovery, personalizing treatments, and boosting efficiency. Global pharmaceutical revenues are projected to reach $1.16 trillion this year, with a <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">6.2% CAGR</a>, also reaching $1.47 trillion by 2028.
In addition, advancements in biopharmaceuticals and biomedical science are driving cutting-edge therapies, such as cell and gene therapies, stem cell technologies, and regenerative and precision medicines. These innovations are propelling the pharmaceutical industry's growth, with the global biotechnology market projected to reach <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">$3.88 trillion by 2030</a>, growing at a CAGR of 14%.
Considering these conducive trends, let's take a look at the fundamentals of the three pharmaceutical picks.
AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>)
ABBV discovers, develops, manufactures, and sells pharmaceuticals worldwide. It offers a diverse range of pharmaceutical products, including treatments for autoimmune diseases, dermatology, rheumatology, oncology, neuroscience, eye care, gastroenterology, and endocrinology. Some of the products in its portfolio are HUMIRA, SKYRIZI, and RINVOQ.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin, ABBV's 32.01% is considerably higher than the 2.78% industry average. Likewise, its 35.70% trailing-12-month levered FCF margin is significantly higher than the 1.66% industry average. Furthermore, its 69.66% trailing-12-month gross profit margin is 20.7% higher than the 57.70% industry average.
ABBV's net revenues for the fiscal second quarter that ended on June 30, 2024, increased 4.3% year-over-year to $14.46 billion. Its operating earnings for the period were $4 billion, and its adjusted earnings after tax were $4.71 billion. Additionally, its adjusted EPS was $2.65.
Street expects ABBV's revenue for the quarter ended September 30, 2024, to increase 2.4% year-over-year to $14.27 billion. Its EPS for the quarter ending December 31, 2024, is expected to grow 5.7% year-over-year to $2.95. Over the past year, ABBV's stock has gained 32.8% to close the last trading session at $196.82.
ABBV's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect strong prospects. It has an overall rating of A, translating to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It is ranked #3 out of 159 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry. It has a B grade for Growth, Value, Stability, Sentiment, and Quality. <a href="https://stocknews.com/stock/ABBV/">Click here</a> to see ABBV's Momentum ratings.
Bristol-Myers Squibb Company (<a href="https://stocknews.com/stock/BMY/">BMY</a>)
BMY discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases.
On September 26, 2024, BMY announced FDA approval of COBENFY, a first-in-class treatment for schizophrenia. COBENFY introduces a new pharmacological approach, offering improved symptom reduction and safety.
In terms of the trailing-12-month levered FCF margin, BMY's 33.74% is significantly higher than the 1.66% industry average. Its 0.49x trailing-12-month asset turnover ratio is 19.9% higher than the 0.41x industry average. Also, its 76.18% trailing-12-month gross profit margin is 32% higher than the 57.70% industry average.
During the second quarter that ended June 30, 2024, BMY's total revenues increased 8.7% year-over-year to $12.20 billion. Its non-GAAP gross profit rose 9.6% from the year-ago value to $9.23 billion. For the same quarter, its non-GAAP net earnings attributable to BMY and non-GAAP EPS came in at $4.19 billion and $2.07, up 14.1% and 18.3% over the prior year's quarter, respectively.
For the quarter ended September 30, 2024, BMY's revenue is expected to increase 2.8% year-over-year to $11.27 million. Its EPS for fiscal 2025 is expected to rise 822.5% year-over-year to $7. It surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past three months, the stock has gained 32.9% to close the last trading session at $53.76.
BMY's POWR Ratings reflect a robust outlook. It has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has an A grade for Growth and a B for Value, Sentiment, and Quality. It is ranked #5 in the Medical – Pharmaceuticals industry. To see BMY's additional grades for Momentum and Stability, <a href="https://stocknews.com/stock/BMY/">click here</a>.
Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
On September 10, 2024, GILD announced a strategic collaboration with Genesis Therapeutics to leverage AI for discovering and developing novel small molecule therapies. GILD gained exclusive rights to develop and commercialize resulting products from the collaboration.
On August 14, 2024, GILD announced the FDA's accelerated approval of Livdelzi (seladelpar) for treating primary biliary cholangitis in adults. The drug demonstrated significant reductions in key biomarkers and pruritus compared to placebo.
In terms of the trailing-12-month EBITDA margin, GILD's 48.42% is 654.8% higher than the 6.41% industry average. Likewise, its 77.44% trailing-12-month gross profit margin is 34.2% higher than the 57.70% industry average. Additionally, its 0.48x trailing-12-month asset turnover ratio is 16.3% higher than the 0.41x industry average.
For the fiscal second quarter (ended June 30, 2024), GILD's total revenues increased 5.4% year-over-year to $ 6.95 billion. The company's non-GAAP operating income came in at $3.27 billion, up 43.4% from the previous year's quarter. In addition, its non-GAAP net income attributable to GILD stood at $2.52 billion or $2.01 per share, up 49.2% and 50% year-over-year, respectively.
Analysts expect GILD's revenue for the quarter ending December 31, 2024, to increase marginally year-over-year to $7.16 billion. Its EPS for fiscal 2025 is expected to grow 87.7% year-over-year to $7.14. It surpassed the Street EPS estimates in three of the trailing four quarters. Over the past three months, GILD's stock has gained 28.9% to close the last trading session at $84.74.
It's no surprise that GILD has an overall rating of A, which translates to a Strong Buy in our proprietary POWR Ratings system.
It has an A grade for Value and a B for Sentiment and Quality. It is ranked #5 out of 334 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. Beyond what we stated above, we also have given GILD grades for Growth, Momentum, and Stability. Get all the GILD's ratings <a href="https://stocknews.com/stock/GILD/">here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
ABBV shares were trading at $195.32 per share on Thursday afternoon, down $1.50 (-0.76%). Year-to-date, ABBV has gained 29.61%, versus a 20.31% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/abbv-bmy-gild-3-pharmaceutical-stocks-that-could-lead-the-next-drug-revolution/>3 Pharmaceutical Stocks That Could Lead the Next Drug Revolution</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Pharmaceutical Stocks That Could Lead the Next Drug Revolution

Companies that are set to benefit from lower interest rates, doesn't necessarily mean those are all the companies that will outperform all others, it's just who really stands to gain here.

3 Industries Set To Explode When Interest Rates Drop

The healthcare industry is set for growth due to the growing demand for quality healthcare services and ongoing advancements in medical technology. Hence, investors might consider investing in healthcare stocks, Johnson & Johnson (JNJ), AbbVie (ABBV), and Thermo Fisher Scientific (TMO) for safe and steady growth. Read more… Healthcare services are necessities, not luxuries, meaning demand is consistent regardless of economic conditions. People need medical care, pharmaceuticals, and health-related services regardless of the economic climate, making it a recession-resistant sector.
Given this backdrop, it could be wise to consider investing in fundamentally strong healthcare stocks, Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>), AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>), and Thermo Fisher Scientific Inc. (<a href="https://stocknews.com/stock/TMO/">TMO</a>).
The demand for healthcare services and products is growing, driven by factors like a global aging population, escalating healthcare expenses, and ongoing advancements in medical technology. Therefore, <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">global pharmaceuticals market revenue</a> is anticipated to increase at a CAGR of 4.7%, reaching $1.45 trillion by 2029.
The <a href="https://www.biospace.com/u-s-pharmaceutical-market-size-to-reach-usd-1-093-79-billion-by-2033">United States leads the world</a> in per capita prescription drug spending, accounting for 30-40% of the global market and 45% of global pharmaceutical sales, with 22% of global production. As a result, companies producing or providing these specialized drug solutions are experiencing consistent growth.
Diagnostics also plays a crucial role, which is why the global clinical diagnostics market size is worth $86.72 billion in 2024 and is projected to reach around $140.53 billion by 2033, <a href="https://www.biospace.com/clinical-diagnostics-market-size-to-hit-usd-140-53-billion-by-2033">expanding at a CAGR of 5.5%</a> between the two periods.
Given these favorable industry trends, let's look at the fundamentals of three healthcare stocks.
Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ is engaged in researching, developing, manufacturing, and selling healthcare products primarily focused on human health and well-being. The company offers a diversified range of products through the Innovative Medicine and MedTech segments.
On September 30, 2024, JNJ announced it had expanded the roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC - IOL), TECNIS Odyssey, in the United States. The new full visual range IOL&#x2A;1 offers patients an unmatched continuous full range of vision, so they can see clearly from far to near and between, minimizing their need for glasses.
On August 20, JNJ announced its acquisition of V-Wave Ltd., a privately held company specializing in innovative heart failure treatment. The deal includes an upfront payment of $60 million, with the potential for additional payments of up to $1.1 billion. This acquisition is set to enhance JNJ MedTech's position in the cardiovascular space, broadening its portfolio of advanced heart failure treatment options.
For the second quarter of 2024, which ended on June 30, JNJ's sales to customers increased 4.3% year-over-year to $22.45 billion. Its <a href="https://www.investopedia.com/terms/g/grossprofit.asp#:~:text=Gross%20profit%2C%20or%20gross%20income,fluctuate%20compared%20to%20production%20output.">gross profit</a> rose 3.5% from the year-ago value to $15.58 billion.
The company's adjusted net earnings from continuing operations amounted to $6.84 billion, representing a marginal increase from the same period last year. Also, its adjusted net earnings per share from continuing operations for the quarter increased 10.2% year-over-year to $2.82.
As per the updated guidance for the fiscal year 2024, JNJ forecasts operational sales between $89.20 billion and $89.60 billion, a 6% increase from 2023, primarily driven by recent acquisitions. The company also expects adjusted EPS between $9.97 and $10.07.
The consensus revenue estimate of $22.47 billion for the fiscal fourth quarter (ending December 2024) represents a 5% increase year-over-year. The company expects its EPS to be $2.28. The company has an impressive earnings surprise history; it surpassed the consensus EPS estimates in each of the trailing four quarters.
Over the past three months, the stock has surged 10.1%, closing the last trading session at $161.17.
JNJ's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its promising outlook. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
JNJ has a B grade for Value, Stability, and Quality. It is ranked #17 out of 159 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/JNJ/">Click here</a> to see the additional ratings for JNJ (Growth, Momentum, and Sentiment).
AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>)
ABBV is a global diversified research-based biopharmaceutical company engaged in manufacturing and selling medications and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties.
On August 19, ABBV received conditional marketing authorization from the EC for TEPKINLY (epicoritamab). This approval marks the first and only subcutaneous bispecific antibody granted such status as a monotherapy for treating both relapsed or refactory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL) after two or more prior therapies.
In the same month, ABBV announced the acquisition of Cerevel Therapeutics (<a href="https://stocknews.com/stock/CERE/">CERE</a>) to strengthen its position in neuroscience and expand its portfolio in psychiatry, migraine, and Parkinson's disease, bolstering its existing pipeline and market presence.
For the six-month period that ended on June 30, 2024, ABBV's net revenue increased 2.6% year-over-year to $26.77 billion, while the company's Neuroscience segment reported net revenue of $4.13 billion, indicating a 15.3% growth from the prior-year period.
ABBV's attributable net income came in at $2.74 billion, up 21% year-over-year, while its earnings per share attributable grew 21.4% from the year-ago value to $1.53.
Looking ahead, ABBV raised its adjusted EPS to range between $10.71 and $10.91 from the prior forecast of $10.61 and $10.81.
Street expects ABBV's revenue and EPS for the fiscal fourth quarter (ending December 2024) to increase 2.4% and 5.7% year-over-year to $14.64 billion and $2.95, respectively. Moreover, it beat the revenue estimates in each of the trailing four quarters, which is promising.
Shares of ABBV have gained 27% over the past nine months and 32% over the past year to close the last trading session at $196.82.
ABBV's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
ABBV has a B grade for Growth, Value, Sentiment, Stability, and Quality. It is ranked #3 out of 159 stocks in the Medical - Pharmaceuticals industry.
In addition to the POWR Ratings we've stated above, we also have ABBV ratings for Momentum. Get all ABBV ratings <a href="https://stocknews.com/stock/ABBV/">here</a>.
Thermo Fisher Scientific Inc. (<a href="https://stocknews.com/stock/TMO/">TMO</a>)
TMO is engaged in helping life sciences research, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies globally. It operates through four segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Biopharma Services.
On July 10, TMO acquired Olink Holding AB (<a href="https://stocknews.com/stock/OLK/">OLK</a>), a leading provider of next-generation proteomics solutions, in a transaction valued at approximately $3.10 billion, net of $96 million in acquired cash.
This acquisition will be integrated into TMO's Life Sciences Solutions segment. This move enhances TMO's capabilities in the rapidly growing proteomics market, accelerating scientific discoveries and boosting shareholder value.
For the second quarter of 2024, which ended on June 29, TMO's operating income increased 15.3% year-over-year to $1.82 billion. Its adjusted net income for the quarter amounted to $2.06 billion, representing an increase of 3% from the same period last year, while its adjusted EPS stood at $5.37, up 4.3% year-over-year. Also, the company's non-GAAP free cash flow grew 32.8% from the year-ago value to $1.67 billion.
Building on this quarter's momentum and successful acquisition, the company updated its annual guidance for 2024. TMO anticipates full-year revenue to range between $42.40 billion and $43.30 billion. It also forecasts adjusted EPS in the range of $21.29 to $22.07, slightly higher than the prior forecast of $21.14 to $22.02.
The consensus revenue estimate of $11.35 billion for the fiscal fourth quarter (ending December 2024) represents a 4.2% increase year-over-year. The consensus EPS estimate of $5.98 for the same quarter indicates a 5.5% improvement year-over-year. The company has an impressive earnings surprise history; it surpassed the consensus EPS estimates in each of the trailing four quarters.
Over the past nine months, the stock has surged 15.4%, closing the last trading session at $612.72.
TMO's POWR Ratings reflect its bright outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. 
TMO has a B grade for Stability and Sentiment. It is ranked #8 out of 39 stocks in the <a href="https://stocknews.com/category/medical-diagnostics-research/">Medical - Diagnostics/Research</a> industry. <a href="https://stocknews.com/stock/TMO/">Click here</a> to see the additional ratings for TMO (Growth, Value, Momentum, and Quality). 
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
JNJ shares were trading at $160.52 per share on Thursday afternoon, down $0.65 (-0.40%). Year-to-date, JNJ has gained 4.81%, versus a 20.38% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/jnj-abbv-tmo-cere-olk-3-healthcare-stocks-for-safe-steady-growth/>3 Healthcare Stocks for Safe, Steady Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks for Safe, Steady Growth

AbbVie lowers 2024 earnings forecast by $0.04 per share

American pharmaceutical giant AbbVie ($ABBV) abruptly lowered its Q3 and full year Fiscal 2024 earnings expectations owing to higher R&D (research ...

AbbVie Lowers Q3 and FY24 Earnings Estimates Amid Higher R&D Charges

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

ADVM

BMYMP

CERE

DELL

FDMT

GILD

RGNX

Screenshot 2024-05-14 at 6.27.53 PM

BRTX

CYNO

BioRestorative Therapies (NASDAQ: BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

Screenshot 2024-02-24 at 12.03.42 AM

AXSM

TNXP

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Press Releases

Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns

New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement

AbbVie and SpinUp Foster Canadian Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award

AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

AbbVie to Host Third-Quarter 2024 Earnings Conference Call

Opinion

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition

Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing

Allergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM

Comments

AbbVie

매도 수량

AbbVie (NYSE:ABBV) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌